- Home
- LANV vs ABOS Comparison
LANV vs ABOS Comparison
Compare LANV & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- ABOS
- Stock Information
- Founded
- LANV 2015
- ABOS 1996
- Country
- LANV China
- ABOS United States
- Employees
- LANV N/A
- ABOS N/A
- Industry
- LANV Blank Checks
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- ABOS Health Care
- Exchange
- LANV Nasdaq
- ABOS Nasdaq
- Market Cap
- LANV 219.4M
- ABOS 99.1M
- IPO Year
- LANV N/A
- ABOS 2021
- Fundamental
- Price
- LANV $1.85
- ABOS $1.56
- Analyst Decision
- LANV
- ABOS Strong Buy
- Analyst Count
- LANV 0
- ABOS 3
- Target Price
- LANV N/A
- ABOS $9.33
- AVG Volume (30 Days)
- LANV 92.6K
- ABOS 379.4K
- Earning Date
- LANV 02-19-2025
- ABOS 11-12-2024
- Dividend Yield
- LANV N/A
- ABOS N/A
- EPS Growth
- LANV N/A
- ABOS N/A
- EPS
- LANV N/A
- ABOS N/A
- Revenue
- LANV $409,961,427.00
- ABOS N/A
- Revenue This Year
- LANV N/A
- ABOS N/A
- Revenue Next Year
- LANV $10.45
- ABOS N/A
- P/E Ratio
- LANV N/A
- ABOS N/A
- Revenue Growth
- LANV N/A
- ABOS N/A
- 52 Week Low
- LANV $0.91
- ABOS $1.54
- 52 Week High
- LANV $3.78
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- LANV 46.31
- ABOS 30.29
- Support Level
- LANV $1.69
- ABOS $1.69
- Resistance Level
- LANV $2.09
- ABOS $1.88
- Average True Range (ATR)
- LANV 0.24
- ABOS 0.13
- MACD
- LANV -0.04
- ABOS -0.00
- Stochastic Oscillator
- LANV 25.97
- ABOS 4.88
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.